Skip to Content

Veverimer Approval Status

FDA Approved: No
Generic name: veverimer
Company: Tricida, Inc.
Treatment for: Metabolic Acidosis

Veverimer (TRC101) is a non-absorbed, orally-administered polymer in development for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).

Development Status and FDA Approval Process for veverimer

DateArticle
Sep  4, 2019Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease
Jun 25, 2019Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide